1. Home
  2. UEIC vs BOLD Comparison

UEIC vs BOLD Comparison

Compare UEIC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$4.31

Market Cap

60.6M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.89

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
BOLD
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
60.6M
60.8M
IPO Year
1995
2024

Fundamental Metrics

Financial Performance
Metric
UEIC
BOLD
Price
$4.31
$2.89
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$3.50
$4.00
AVG Volume (30 Days)
97.9K
233.9K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
23.78
32.47
EPS
N/A
N/A
Revenue
$368,288,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$0.96
52 Week High
$5.99
$3.16

Technical Indicators

Market Signals
Indicator
UEIC
BOLD
Relative Strength Index (RSI) 38.77 65.15
Support Level $3.87 $2.71
Resistance Level $4.43 $2.97
Average True Range (ATR) 0.33 0.14
MACD -0.11 -0.01
Stochastic Oscillator 4.35 41.63

Price Performance

Historical Comparison
UEIC
BOLD

About UEIC Universal Electronics Inc.

Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: